Vnitr Lek 2010, 56(6):513-516

Pulmonary hypertension - unusual complication of haemolysis and the bacterial overgrowth syndrome

V. Kojecký*, M. Lukaštíková
Interní klinika IPVZ Praha, Krajská nemocnice T. Bati, a.s., Zlín, přednosta doc. MUDr. Čestmír Čihalík, CSc.

The authors describe a case of a patient with celiac disease in whom a secondary bacterial overgrowth had developed in the small intestine. Vitamin B12 and folic acid consumption deficiency resulted in a development of macrocytary anaemia and non-immune haemolysis. Subsequently, within a few weeks, a significant pulmonary hypertension has developed, the cause of which was first unclear. Haemolysis as well as pulmonary hypertension ceased following bacterial overgrowth treatment and B12 and, later on, folic acid substitution. Retrospectively, the authors infer that this could have been the haemolytic anaemia-associated pulmonary hypertension syndrome.

Keywords: pulmonary hypertension; haemolysis; celiac disease

Received: December 14, 2009; Accepted: March 3, 2010; Published: June 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kojecký V, Lukaštíková M. Pulmonary hypertension - unusual complication of haemolysis and the bacterial overgrowth syndrome. Vnitr Lek. 2010;56(6):513-516.
Download citation

References

  1. Halfdanarson TR, Litzow MR, Murray JA. Hematologic manifestations of celiac disease. Blood 2007; 109: 412-421. Go to original source... Go to PubMed...
  2. Hoffbrand AV, Tabaqchali S, Booth CC et al. Small intestinal bacterial flora and folate status in gastrointestinal disease. Gut 1971; 12: 27-33. Go to original source... Go to PubMed...
  3. Klipstein FA, Samloff IM. Folate synthesis by intestinal bacteria. Am J Clin Nutr 1966; 19: 237-246. Go to original source... Go to PubMed...
  4. Jansa P, Aschermann M, Riedel M et al. Doporučení pro diagnostiku a léčbu plicní arteriální hypertenze v ČR. Cor Vasa 2004; 46: K35-K44.
  5. Castro O, Hoque M, Brown BD. Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood 2003; 101: 1257-1261. Go to original source... Go to PubMed...
  6. Řiháček I, Souček M, Kára T et al. Primární plicní hypertenze - aktuální pohled na diagnostiku a léčbu. Vnitř Lék 2003; 49: 482-489. Go to PubMed...
  7. Rother RB, Bell L, Hillmen P et al. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 2005; 293: 1653-1662. Go to original source... Go to PubMed...
  8. Gladwin MT, Sachdev V, Jison ML et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004; 350: 886-895. Go to original source... Go to PubMed...
  9. Morris CR. Mechanisms of vasculopathy in sickle cell disease and thalassemia. Hematology Am Soc Hematol Educ Program 2008; 1: 177-185. Go to original source... Go to PubMed...
  10. Morris CR, Gladwin MT, Kato GJ. Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders. Curr Mol Med 2008; 8: 620-632. Go to original source... Go to PubMed...
  11. Tofovic SP, Jackson EK, Rafikova O. Adenosine deaminase-adenosine pathway in hemolysis-associated pulmonary hypertension. Med Hypotheses 2009; 72: 713-719. Go to original source... Go to PubMed...
  12. Slebos DJ, Ryter SW, Choi AM. Heme oxygenase-1 and carbon monoxide in pulmonary medicine. Respir Res 2003; 4: 7. Go to original source... Go to PubMed...
  13. Kato GJ, Gladwin MT. Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy. JAMA 2008; 300: 2638-2646. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.